Your browser doesn't support javascript.
loading
Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis.
Artigo em Inglês | IMSEAR | ID: sea-124593
ABSTRACT

BACKGROUND:

A combination of Peginterferon and Ribavirin is the standard treatment for patients with chronic hepatitis C viral infection (HCV). Ribavirin is contraindicated in patients with chronic renal failure (CRF). Conventional Interferon monotherapy is effective in around 30% of such patients. There is scanty data on the use of Peginterferon monotherapy in them.

METHODS:

We describe our preliminary experience of monotherapy with Peginterferon alpha- 2b {12 kDa} (Peg-IFN) for HCV patients undergoing haemodialysis for CRF. They were treated with Peg-IFN 1 microg/kg body weight subcutaneously once a week for 24 weeks. In all patients, clinical (age, sex, mode of acquiring HCV, pattern of haemodialysis) and virological (HCV RNA quantitative-PCR and genotype) profile was noted at baseline. Early virological response at 12 weeks (EVR), end-of-treatment virological response at 24 weeks (ETVR) and sustained virological response after 6 months of stopping treatment (SVR) were noted during the follow-up period.

RESULTS:

The clinical and virological characteristics of patients were as follows Of a total number of 6 patients, 5 were male and 1 was female with an age range of 35 to 62 years. The duration of haemodialysis was from between 5 and 12 months before the start of treatment and its frequency lay between 1 and 3 times a week. The mode of acquiring HCV was blood transfusion (100%). All 6 cases suffered from chronic hepatitis. The genotype distribution was genotype 3 in 3 (50%), genotype 1 in 1 (16.7%) and genotype none of 6 in 2 (33.3%) patients. All the patients (100%) completed treatment. EVR was seen in all 6 patients (100%). ETVR was seen in 5 of 6 patients (83.3%). A follow-up period of more than 1 year was available in 4 patients. 3 of these 4 patients (75%) had SVR. A virological response was maintained in all 3 (100%) patients with SVR even after 6 months of renal transplantation.

CONCLUSION:

Peg-IFN monotherapy is safe and effective in patients with HCV who are on haemodialysis for CRF.
Assuntos
Texto completo: DisponíveL Índice: IMSEAR (Sudeste Asiático) Assunto principal: Antivirais / Feminino / Humanos / Masculino / RNA Viral / Reação em Cadeia da Polimerase / Estudos Prospectivos / Seguimentos / Diálise Renal / Resultado do Tratamento Tipo de estudo: Estudo observacional / Estudo prognóstico / Fatores de risco Idioma: Inglês Ano de publicação: 2007 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: IMSEAR (Sudeste Asiático) Assunto principal: Antivirais / Feminino / Humanos / Masculino / RNA Viral / Reação em Cadeia da Polimerase / Estudos Prospectivos / Seguimentos / Diálise Renal / Resultado do Tratamento Tipo de estudo: Estudo observacional / Estudo prognóstico / Fatores de risco Idioma: Inglês Ano de publicação: 2007 Tipo de documento: Artigo